{"ticker": {"uuid": "4c1c9d9b-6910-4e53-9189-ad6ee63a30cb", "symbol": "VERA", "name": "Vera Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA\u2019s Accelerated FDA Approval - Learn Why", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T09:52:41+00:00", "published_display": "16 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vera Bradley (NASDAQ:VRA) Stock Rating Upgraded by Wall Street Zen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUDUzZmt6X2hTV3VKN1VpZmdKaF9pU0tMZ1M1anN0MHlRWVZWb2F2NWN5MzlaeGkyQWdWM1VYdHp0SVFjY2VQdXJvdy01ZmRsOERKTVFaSVFWajFLME5fdEhraHVOQTRULXBNLS14Y25oYUtSTlF1TnFVS2FPWnpsdXE5T1lzbENldHRaTzNGbFgwejVvVGp0WG9vZW1fOEl1U0N5VGQyREwyQ2xRUWpLZkVXbzU2OTAw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T17:33:21+00:00", "published_display": "12 Jul 2026 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch", "summary": "", "url": "https://finance.yahoo.com/m/846d0c37-cb09-36d9-88e6-8c0ce903de49/vera-therapeutics-wins-fda.html", "source_name": "MarketBeat", "published_at": "2026-07-11T18:02:05+00:00", "published_display": "11 Jul 2026 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to eight new employees. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The stock options and RSUs will", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-inducement-grants-200500737.html", "source_name": "Market source", "published_at": "2026-07-10T20:05:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Vera Therapeutics employees receive $40.13 stock options in inducement plan", "summary": "Vera Therapeutics announced that its Board Compensation Committee granted inducement equity awards to eight new employees on July 6, 2026. These awards include non-qualified stock options for 32,100 Class A shares with an exercise price of $40.13 and RSUs for 16,050 Class A share", "url": "https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-k6dimb60x7zk.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:19", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-accelerated-approval-trutakna-transforming-171255169.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T17:12:55+00:00", "published_display": "10 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced?", "summary": "Vera Therapeutics (VERA) has received accelerated FDA approval for TRUTAKNA, its first commercial product for primary IgA nephropathy. Despite a year-to-date share price decline of 12.73%, the company has seen a 1-month rebound of 33.39% following the approval and a 74.25% one-ye", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-wins-fda-approval-for-trutakna-is-the-stock-fully-priced-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T16:39:19", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-vera-could-92-141401352.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T14:14:01+00:00", "published_display": "10 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOVS1kVjZOc191YTBERTltdV8wYVFmR2NJWlV0dXRkVjR1ZVcteWxleklXR3ZzV09yRkxmYkw1bFBsTEJjUDZJS2t5YWpCUU15RGZkNi1aa09mMm9vYW1QRjVvTEZHYXhqbEx5WjlMMjF5ME93MjZ2NGt6emM2UXdqNjU3bHl4OXlFSkdDRXR6bWxCQUFpR2FPUU9wRQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million", "summary": "Vera Therapeutics CEO Fordyce Marshall sold approximately $1.96 million worth of Class A Common Stock on July 7, 2026, under a pre-arranged trading plan. Despite the sale, the stock is considered undervalued by InvestingPro, and the company recently received FDA approval for its ", "url": "https://www.investing.com/news/insider-trading-news/vera-therapeutics-ceo-fordyce-marshall-sells-shares-worth-196-million-93CH-4784956", "source_name": "Investing.com", "published_at": "2026-07-09T22:43:21", "published_display": "09 Jul 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported", "summary": "Vera Therapeutics CEO Marshall Fordyce reported the sale of 46,250 shares of Class A common stock on July 7, 2026, through a pre-planned trading arrangement (Rule 10b5-1(c)). The shares were sold at weighted-average prices between $40.39 and $43.97. Following these transactions, ", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-e6346d9c2fc5.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:03:32", "published_display": "09 Jul 2026 21:03", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNR3VsZmQ2TF85TFNFLTJ1dno5enlwOHhmQ0RHbHpHZGpCM3Ytbm5vc0NqbUJSN2FoQmdFazJLejhRYmtGNXJ1bzlneG1UaWJIV3VWcjJibUdxaTh2ejVRMURLSDFyVmF2ZkVNTHItUmN2ODB0ZmhySWtCSnBKZ05qNGtOLUptUVhhVGdHMDY4RHV2OXl6Ui1DUVBtTXQtWlFJdkJjbzk1N1Y0S3h6Wnlj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:39+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-appointment-nancy-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Proxy filing Summary", "summary": "Vera Therapeutics (VERA) has scheduled its annual meeting for May 21, 2026, where shareholders will vote on the election of three Class II directors, the ratification of KPMG LLP as the 2026 auditor, and an advisory vote on executive compensation. Only Class A common stock holder", "url": "https://quartr.com/events/vera-therapeutics-inc-vera-proxy-filing_F3sCt02f", "source_name": "Quartr", "published_at": "2026-07-09T10:40:13", "published_display": "09 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-apos-trutakna-pricing-190311245.html", "source_name": "MT Newswires", "published_at": "2026-07-08T19:03:11+00:00", "published_display": "08 Jul 2026 19:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOSkFtbERsMEFRNEJwanF3UDRTWGFrc2lZUlI0dUVNejVjOXlNT2R1cHBmWjJERjhZSWM5T3h5UGpTbWhJWjJOakdwOVp3V0kzMS1odWR5aDNKb3NQbkNrYWRSZXdJZDlfelRqVE9sOTYtODBITXBIMVpTTFhQeEk1QTRmemhoa0ZvOENJcEprWHQzMWVfSlVFSS16d1g1bC1keEJTclIyeXNUZy16XzlWdkcyYmE2S1JBckU1Z2VNUmxfcnY5LUVKYWd4ZEVMVUZNbWc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T13:03:43+00:00", "published_display": "08 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Vera Therapeutics stock price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQNlBidXhqdUdXZlBBNUM5bXdscFRNQkgwSlFGRjhKTVpBQVNvZlZYUkt1WVVNb1RUaHRuSHpJN3lFWHRxMjZCU043b3dST2RhaGhoTklCakM1SEZUN3JxbUV6djhjd1RDNHFreDV1WlZiQlJFSHFQWmV2MUdvOVc2ZHRacXh4UTJycWZUMUV4cEVJYW96RnZaNGZtekFzM3MzZXNJTXl1YVVQMDlVRHY0SE5DTlZhZ0RqeF83SnRjNi1EWFhjTl9GdWl3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T11:46:37+00:00", "published_display": "08 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Vera Therapeutics to $43 From $35, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wedbush-raises-price-target-vera-104914308.html", "source_name": "MT Newswires", "published_at": "2026-07-08T10:49:14+00:00", "published_display": "08 Jul 2026 10:49", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRUTAKNA\u2019s Dual-Pathway FDA Nod Could Be A Game Changer For Vera Therapeutics (VERA)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T01:51:21+00:00", "published_display": "08 Jul 2026 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Vera Therapeutics Stock Gaining Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRURwZnlWQl9JU1p1ZlBwbER4aGNHV0J3Mm5OQmFVcVQ2cGVwRmYyaS1jWGtQN3huSF9UTnZXU3dyZGl0Q3lYaHFjZEJoTXVqcVc1Qk45bkc4aVVYOS1KNUxhTmppZXR3SXBBbWxxdFFEdU9DNUx0Z2wwYkFtS3dPeVp4aFJqLUJ1aUxjcDNSNXE2NUhuR3lWeHMwcw?oc=5", "source_name": "Benzinga", "published_at": "2026-07-07T18:15:10+00:00", "published_display": "07 Jul 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale", "summary": "Vera Therapeutics Inc. (NASDAQ: VERA) stock has risen by 9.52% due to positive clinical trial progress, despite its CEO, Marshall Fordyce, selling 18,500 shares for $701,769. Fordyce still retains a significant stake of over 420,000 shares, suggesting the sale is a profit-taking ", "url": "https://stockstotrade.com/news/vera-therapeutics-inc-vera-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T18:10:00", "published_display": "07 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going on with Vera Therapeutics Stock on Monday?", "summary": "Vera Therapeutics Inc. (NASDAQ: VERA) stock is gaining momentum as the company awaits a key FDA decision for its rare kidney disease drug, atacicept. The FDA's action date is July 7 for accelerated approval of atacicept for IgA Nephropathy, supported by positive data from the ORI", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-vera-therapeutics-stock-on-monday-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T22:39:19", "published_display": "06 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics stock rises ahead of FDA decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORW9rZUxzd2ZGV1hnZVVlbTROOGttZDJ3YkNHTy1lWHJIcVNodjU5WHRZZERjb2NiUVNSN3FxLTdxNTk4Uk1NSURrd3Bkc3pONkVsUjNvX2hDbTU4S3BOV285VzJfNzlRVEZMd253NUpmN0VMNW5zNjRhM1o1WVdrWFlscTdUQXpMM0FPMWQ2WU02V3B0enNpdzN6ekZHTUtpWGlyM3I2ck1fUjdFTzhFbzg4Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVGd4TUFSSzdUUks1aFRXMlJ0YXdvZkxPUXFXcHBYM2ttbWF1eE4wTE8zTF9VRG5FUFpkQ3huZzVwcHFhd05uQjNaVW41OFdfRE1paXczU2VBWXkyQVl5ZmNJb2RaVnNleWZtQTZqX2xxWkNMcUpLdkhXSG80Zmh2bV9lTDZNVGZpNlJKRWlpaGJKR2R4TmpLQ05uczRIUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQRk9vb1djZGtXRHJZWVBXSXNiRE81NmU4VV9rd3lDR2tIb3RQMzJYYjJKbXQtcnNYbFdsZDl5VmFaM0g5cG9ydlNFcDZjcWNySTNnOXZIN3JDRzU0Zk91ZHZzZE1LaG56SVMybVltdUE0UTM1OEp1NHNERTh5ZlgtaVpkZ01xUU9uM216R1duYUN5UjVuYTJr?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)", "summary": "This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-VERA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:04", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan", "summary": "Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Fo", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-514f82bd1df3.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:10:44", "published_display": "25 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock", "summary": "Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory ", "url": "https://m.uk.investing.com/news/stock-market-news/vera-therapeutics-president-and-ceo-fordyce-marshall-sells-701769-in-stock-93CH-4743230?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T05:10:30", "published_display": "25 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERA (NASDAQ: VERA) plans resale of 74,000 shares via option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQdFRUcGdwTFdtOTNsci15YU5pTG1ueDg0RElGWDlhMWh1by1xOXRrTVh0cEtLSWpzOXRpbWRDeUt6VTR2RmJZNnE0am9rbTc0dHJjUzZDV3JmOW12d3g2dVVDU3ozR2U1MHdiamZNWWp6djJzVV9sTTdMZGJudHNVRlA5cDNyUi1xSFpRZTZGS2dLY3lVVVV0MklmTlpjeWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?", "summary": "Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track ful", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-is-up-107-after-accelerated-fda-timeline-for-atacicept-igan-filing-has-the-bull-case-changed-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T14:40:45", "published_display": "19 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Appears Attractive After Latest FDA Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPSmcteldtZFZYVXNScUNxWlpTbmxMbWhwYlAtUjhVUHhOY2NtSWZPcURLZTdJci1MSWoyekVnOXRZbm5wdzVHSWlfeThpcThZVTJDZXppREVGY1pMV0l5X2dIWTR0Zm13S1p5cXJQcHpIU3RUcXFVWGF6ZUlTbVc0YXkyUHUwbmdCdXVOdnlOY3lrS2h3OXBlaG40dDY0anhqdHk5aA?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far", "summary": "Vera Therapeutics (VERA) is seeing investor interest after reaching an agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial. While recent stock performance shows a 7.84% rise over 7 days, it's down over 90 days and year-to-date, contrasting with strong longer", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-stock-after-fda-trial-update-has-the-valuation-gap-gone-too-far-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-16T14:39:01", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com", "summary": "Fordyce Marshall, President and CEO of Vera Therapeutics, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, through a pre-arranged trading plan. Despite the insider sale and a year-to-date decline, the stock has seen an 81% return over the past year and i", "url": "https://uk.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-sells-679747-in-stock-93CH-4676593", "source_name": "Investing.com UK", "published_at": "2026-06-07T09:42:27", "published_display": "07 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics grants inducement awards to 10 new employees", "summary": "Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026. These awards include non-qualified stock options for 28,800 shares with an exercise price of $31.26 and restricted stock units (RSUs) for 14,150 shares. The awards were approved under Nasdaq Listing ", "url": "https://scanx.trade/stock-market-news/companies/vera-therapeutics-grants-inducement-awards-to-10-new-employees/42288284", "source_name": "scanx.trade", "published_at": "2026-06-06T04:14:00", "published_display": "06 Jun 2026 04:14", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Grants Inducement Stock Awards to New Employees", "summary": "Vera Therapeutics granted stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares to ten new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee in accordance with Nasdaq rules, aim to attract talent, with sto", "url": "https://www.quiverquant.com/news/Vera+Therapeutics+Grants+Inducement+Stock+Awards+to+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-06-05T20:12:00", "published_display": "05 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics gives new hires 28,800 stock option shares", "summary": "Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for ten new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants comprise 28,800 stock options at an exercise price of $31.26 and 14,150 Restricted Stock Units (", "url": "https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-d6uclrg70gfb.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:04:52", "published_display": "05 Jun 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy", "summary": "Vera Therapeutics announced alignment with the U.S. FDA for an earlier ORIGIN Phase 3 eGFR analysis for its drug atacicept, aiming for full approval in adults with IgA Nephropathy (IgAN). This revised schedule could lead to an sBLA submission in Q4 2026 and potential full approva", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-announces-alignment-with-us-fda-on-earlier-origin-phase-3-analysis-to-support-potential-full-approval-for-atacicept-in-adults-with-iga-nephropathy-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T20:09:19", "published_display": "02 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQUFM5MUo1UVZ4RjJ3NkJCc0VPOUFNT2syNy1PT1g2ZENJblFTNWtqeUpjaEFRQTU3Rnk3M2VwQWF2M2RjU1ZRWVZvdWFsTEFkX0s3bVF6LXBWVjMwN25RZU5NREZYUUhrY3RIdkJ0WnZPam9tMnV2QjhlLXJkUk1LcjJ6YllCbHNCeWxvaGJaakVlaUx3NWxfME5fUEpob3doSFQxZ2NIT0xaa1oyQTdDOWpuTGdmdXdHeVZka0oxN0hyem5vWmVHd2tVMTlTSmZWRXVKTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORW9UZ1pzODl0Q1hEbWVrcjNIYk5PaXJ0bDFCUFo4TXJQbWwzRHlsX3pxUUg1V3htcmFBV2FpUnhCRXdJVjFacnZfMXM4d3poT0pkQUJnb1dJWi1xNk5RZElyU1JZd1JjX2t2T2NpangwTzRHS2xBVk1hZ0U0cS10d3poLUlFMlZNUUlQV1ZUbmNNSVozTFlGdHpVLWlkREpneTQzSjVOcHhQUHhvVUtv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading", "summary": "Vera Therapeutics (VERA) has granted a stock option for 17,084 shares of Class A Common Stock to director James R. Meyers. The options have an exercise price of $34.35 per share and will expire on May 20, 2036. Vesting is contingent on continuous service, occurring on the earlier", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-d85488941be0.html", "source_name": "Stock Titan", "published_at": "2026-05-29T08:10:15", "published_display": "29 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Vera Therapeutics (VERA) receives grant of 17,084 options", "summary": "Vera Therapeutics director Christy J. Oliger received a grant of 17,084 stock options at an exercise price of $34.35 per share, awarded as compensation. These options will fully vest on the earlier of the first anniversary of the grant date or the company's 2027 annual shareholde", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-12400e3effc7.html", "source_name": "Stock Titan", "published_at": "2026-05-27T18:39:45", "published_display": "27 May 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) awards director 17,084 stock options", "summary": "Vera Therapeutics director Michael Morrissey was granted 17,084 stock options for Class A Common Stock. These options have an exercise price of $34.35 and expire in 2036. They vest fully on the earlier of the first anniversary of the grant date or the company\u2019s 2027 annual stockh", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-3f5981c73657.html", "source_name": "Stock Titan", "published_at": "2026-05-27T04:09:59", "published_display": "27 May 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant", "summary": "Vera Therapeutics director Beth C. Seidenberg was granted stock options for 17,084 Class A common shares with an exercise price of $34.35 per share. These options are part of a compensation package and will vest fully on the earlier of the first anniversary of the grant date or t", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-993cf9cc801a.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:16", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTWh5VlZjZElCcnYyR2NNb0lSWmtmRmhCWnA4TG1LMmhKOE9ZUlVGbnltdDRqWnZqck85cHpJeU9CUEo2blNqbDJlMkFLckN5M3E5V0liWjNSRVhvckpZQTF0Q2ZqVHEybDhJREQ5UDQ3OG9ET3poVEF0UXBmdXNHczc3VE5iUGQ5SEx2TGFacDFORFVGZ25mV2U4SXJ2MnRzZUxBUlZaQkYtYVpBeG9XTTNTWlhLUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQTUFuNGgzYmVqT250SW5GcjJJbWE0ZzdaN1RSTWdMNTZFZzFZSzRzSV9mQjJUX3dyN1lBbEFFZjV2ODhxdGJUVHRoc3FfeDZrazlxVzhjUlhRVFd6U016WVI4LUJ5MVBwMl9vMV9WMVVXbjl2a3Q3QU1wQ1UweEVXOVN6Ylh4MFRjd05rNFlJMm56TlRlUXp6N2djWncwc1doamNNVTdYNFJPeHJMOFR6Ty14YnBDb0pJbUdvc19qWFh0YnptWE5fdFFSazZtR19NZXA1RTBYRTVBU0x4cmRzMlhRYVpMTEdqWFFVVC1meEIzXzlTdnFZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics to present May 13 at Bank of America health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPYUhMaUoyRHFNcjV0UUVPWnk2S2p1c0RiZjdBRlRDMzdGN0gtODlTcHdGMlZuS0tZMDU3UElhZ0hQVGJkQ2JnRlhLcDBzQkxCNmxrMGxaTTVuWjBGX0RnWEJUNDJkVUx1OFhSZUtnZko3TjY4OTlqaE9aVnBzeFZERlRnYmUwX3hlN2E3ckhhR1Q0SERrSkZOaUF2bXdQTmRFeDFHWWZXNkN6d2hpTUZlTFdUNXl0N3hXTndaYnl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPYXV3RFJBQVo1Y0ZUam83R1FvUElLWTdmcHozR1ZvWWxnR25FQmo0NmdyVm43UmtZTGdWZEN5SFJzQ0h2SGRTa1FSUWFvMDFtMTVQck1ydndlTEFMNndwS1FZMk9lRWtVLWI2UGVfVVBaeU50c1lRM2JjVFA3anoweVV3ZG5ZcmFvYjY2Zl80TUlyazhyRExjeUtsYVprZ3hmODhHTjNLOA?oc=5", "source_name": "Market source", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA\u2019s Accelerated FDA Approval - Learn Why", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T09:52:41+00:00", "published_display": "16 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Bradley (NASDAQ:VRA) Stock Rating Upgraded by Wall Street Zen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUDUzZmt6X2hTV3VKN1VpZmdKaF9pU0tMZ1M1anN0MHlRWVZWb2F2NWN5MzlaeGkyQWdWM1VYdHp0SVFjY2VQdXJvdy01ZmRsOERKTVFaSVFWajFLME5fdEhraHVOQTRULXBNLS14Y25oYUtSTlF1TnFVS2FPWnpsdXE5T1lzbENldHRaTzNGbFgwejVvVGp0WG9vZW1fOEl1U0N5VGQyREwyQ2xRUWpLZkVXbzU2OTAw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T17:33:21+00:00", "published_display": "12 Jul 2026 17:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch", "summary": "", "url": "https://finance.yahoo.com/m/846d0c37-cb09-36d9-88e6-8c0ce903de49/vera-therapeutics-wins-fda.html", "source_name": "MarketBeat", "published_at": "2026-07-11T18:02:05+00:00", "published_display": "11 Jul 2026 18:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to eight new employees. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The stock options and RSUs will", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-inducement-grants-200500737.html", "source_name": "Market source", "published_at": "2026-07-10T20:05:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Vera Therapeutics employees receive $40.13 stock options in inducement plan", "summary": "Vera Therapeutics announced that its Board Compensation Committee granted inducement equity awards to eight new employees on July 6, 2026. These awards include non-qualified stock options for 32,100 Class A shares with an exercise price of $40.13 and RSUs for 16,050 Class A share", "url": "https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-k6dimb60x7zk.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:19", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-accelerated-approval-trutakna-transforming-171255169.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T17:12:55+00:00", "published_display": "10 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced?", "summary": "Vera Therapeutics (VERA) has received accelerated FDA approval for TRUTAKNA, its first commercial product for primary IgA nephropathy. Despite a year-to-date share price decline of 12.73%, the company has seen a 1-month rebound of 33.39% following the approval and a 74.25% one-ye", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-wins-fda-approval-for-trutakna-is-the-stock-fully-priced-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T16:39:19", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-vera-could-92-141401352.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T14:14:01+00:00", "published_display": "10 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOVS1kVjZOc191YTBERTltdV8wYVFmR2NJWlV0dXRkVjR1ZVcteWxleklXR3ZzV09yRkxmYkw1bFBsTEJjUDZJS2t5YWpCUU15RGZkNi1aa09mMm9vYW1QRjVvTEZHYXhqbEx5WjlMMjF5ME93MjZ2NGt6emM2UXdqNjU3bHl4OXlFSkdDRXR6bWxCQUFpR2FPUU9wRQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million", "summary": "Vera Therapeutics CEO Fordyce Marshall sold approximately $1.96 million worth of Class A Common Stock on July 7, 2026, under a pre-arranged trading plan. Despite the sale, the stock is considered undervalued by InvestingPro, and the company recently received FDA approval for its ", "url": "https://www.investing.com/news/insider-trading-news/vera-therapeutics-ceo-fordyce-marshall-sells-shares-worth-196-million-93CH-4784956", "source_name": "Investing.com", "published_at": "2026-07-09T22:43:21", "published_display": "09 Jul 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported", "summary": "Vera Therapeutics CEO Marshall Fordyce reported the sale of 46,250 shares of Class A common stock on July 7, 2026, through a pre-planned trading arrangement (Rule 10b5-1(c)). The shares were sold at weighted-average prices between $40.39 and $43.97. Following these transactions, ", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-e6346d9c2fc5.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:03:32", "published_display": "09 Jul 2026 21:03", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNR3VsZmQ2TF85TFNFLTJ1dno5enlwOHhmQ0RHbHpHZGpCM3Ytbm5vc0NqbUJSN2FoQmdFazJLejhRYmtGNXJ1bzlneG1UaWJIV3VWcjJibUdxaTh2ejVRMURLSDFyVmF2ZkVNTHItUmN2ODB0ZmhySWtCSnBKZ05qNGtOLUptUVhhVGdHMDY4RHV2OXl6Ui1DUVBtTXQtWlFJdkJjbzk1N1Y0S3h6Wnlj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:39+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-appointment-nancy-120000541.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Proxy filing Summary", "summary": "Vera Therapeutics (VERA) has scheduled its annual meeting for May 21, 2026, where shareholders will vote on the election of three Class II directors, the ratification of KPMG LLP as the 2026 auditor, and an advisory vote on executive compensation. Only Class A common stock holder", "url": "https://quartr.com/events/vera-therapeutics-inc-vera-proxy-filing_F3sCt02f", "source_name": "Quartr", "published_at": "2026-07-09T10:40:13", "published_display": "09 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vera-therapeutics-apos-trutakna-pricing-190311245.html", "source_name": "MT Newswires", "published_at": "2026-07-08T19:03:11+00:00", "published_display": "08 Jul 2026 19:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOSkFtbERsMEFRNEJwanF3UDRTWGFrc2lZUlI0dUVNejVjOXlNT2R1cHBmWjJERjhZSWM5T3h5UGpTbWhJWjJOakdwOVp3V0kzMS1odWR5aDNKb3NQbkNrYWRSZXdJZDlfelRqVE9sOTYtODBITXBIMVpTTFhQeEk1QTRmemhoa0ZvOENJcEprWHQzMWVfSlVFSS16d1g1bC1keEJTclIyeXNUZy16XzlWdkcyYmE2S1JBckU1Z2VNUmxfcnY5LUVKYWd4ZEVMVUZNbWc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T13:03:43+00:00", "published_display": "08 Jul 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Vera Therapeutics stock price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQNlBidXhqdUdXZlBBNUM5bXdscFRNQkgwSlFGRjhKTVpBQVNvZlZYUkt1WVVNb1RUaHRuSHpJN3lFWHRxMjZCU043b3dST2RhaGhoTklCakM1SEZUN3JxbUV6djhjd1RDNHFreDV1WlZiQlJFSHFQWmV2MUdvOVc2ZHRacXh4UTJycWZUMUV4cEVJYW96RnZaNGZtekFzM3MzZXNJTXl1YVVQMDlVRHY0SE5DTlZhZ0RqeF83SnRjNi1EWFhjTl9GdWl3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T11:46:37+00:00", "published_display": "08 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Vera Therapeutics to $43 From $35, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wedbush-raises-price-target-vera-104914308.html", "source_name": "MT Newswires", "published_at": "2026-07-08T10:49:14+00:00", "published_display": "08 Jul 2026 10:49", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRUTAKNA\u2019s Dual-Pathway FDA Nod Could Be A Game Changer For Vera Therapeutics (VERA)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T01:51:21+00:00", "published_display": "08 Jul 2026 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Vera Therapeutics Stock Gaining Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRURwZnlWQl9JU1p1ZlBwbER4aGNHV0J3Mm5OQmFVcVQ2cGVwRmYyaS1jWGtQN3huSF9UTnZXU3dyZGl0Q3lYaHFjZEJoTXVqcVc1Qk45bkc4aVVYOS1KNUxhTmppZXR3SXBBbWxxdFFEdU9DNUx0Z2wwYkFtS3dPeVp4aFJqLUJ1aUxjcDNSNXE2NUhuR3lWeHMwcw?oc=5", "source_name": "Benzinga", "published_at": "2026-07-07T18:15:10+00:00", "published_display": "07 Jul 2026 18:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale", "summary": "Vera Therapeutics Inc. (NASDAQ: VERA) stock has risen by 9.52% due to positive clinical trial progress, despite its CEO, Marshall Fordyce, selling 18,500 shares for $701,769. Fordyce still retains a significant stake of over 420,000 shares, suggesting the sale is a profit-taking ", "url": "https://stockstotrade.com/news/vera-therapeutics-inc-vera-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T18:10:00", "published_display": "07 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going on with Vera Therapeutics Stock on Monday?", "summary": "Vera Therapeutics Inc. (NASDAQ: VERA) stock is gaining momentum as the company awaits a key FDA decision for its rare kidney disease drug, atacicept. The FDA's action date is July 7 for accelerated approval of atacicept for IgA Nephropathy, supported by positive data from the ORI", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-vera-therapeutics-stock-on-monday-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T22:39:19", "published_display": "06 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics stock rises ahead of FDA decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORW9rZUxzd2ZGV1hnZVVlbTROOGttZDJ3YkNHTy1lWHJIcVNodjU5WHRZZERjb2NiUVNSN3FxLTdxNTk4Uk1NSURrd3Bkc3pONkVsUjNvX2hDbTU4S3BOV285VzJfNzlRVEZMd253NUpmN0VMNW5zNjRhM1o1WVdrWFlscTdUQXpMM0FPMWQ2WU02V3B0enNpdzN6ekZHTUtpWGlyM3I2ck1fUjdFTzhFbzg4Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVGd4TUFSSzdUUks1aFRXMlJ0YXdvZkxPUXFXcHBYM2ttbWF1eE4wTE8zTF9VRG5FUFpkQ3huZzVwcHFhd05uQjNaVW41OFdfRE1paXczU2VBWXkyQVl5ZmNJb2RaVnNleWZtQTZqX2xxWkNMcUpLdkhXSG80Zmh2bV9lTDZNVGZpNlJKRWlpaGJKR2R4TmpLQ05uczRIUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vera Therapeutics, Inc. (VERA) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQRk9vb1djZGtXRHJZWVBXSXNiRE81NmU4VV9rd3lDR2tIb3RQMzJYYjJKbXQtcnNYbFdsZDl5VmFaM0g5cG9ydlNFcDZjcWNySTNnOXZIN3JDRzU0Zk91ZHZzZE1LaG56SVMybVltdUE0UTM1OEp1NHNERTh5ZlgtaVpkZ01xUU9uM216R1duYUN5UjVuYTJr?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)", "summary": "This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports, ", "url": "https://www.tradingview.com/symbols/NASDAQ-VERA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:04", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan", "summary": "Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Fo", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-514f82bd1df3.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:10:44", "published_display": "25 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock", "summary": "Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory ", "url": "https://m.uk.investing.com/news/stock-market-news/vera-therapeutics-president-and-ceo-fordyce-marshall-sells-701769-in-stock-93CH-4743230?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T05:10:30", "published_display": "25 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VERA (NASDAQ: VERA) plans resale of 74,000 shares via option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQdFRUcGdwTFdtOTNsci15YU5pTG1ueDg0RElGWDlhMWh1by1xOXRrTVh0cEtLSWpzOXRpbWRDeUt6VTR2RmJZNnE0am9rbTc0dHJjUzZDV3JmOW12d3g2dVVDU3ozR2U1MHdiamZNWWp6djJzVV9sTTdMZGJudHNVRlA5cDNyUi1xSFpRZTZGS2dLY3lVVVV0MklmTlpjeWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?", "summary": "Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track ful", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-is-up-107-after-accelerated-fda-timeline-for-atacicept-igan-filing-has-the-bull-case-changed-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T14:40:45", "published_display": "19 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Appears Attractive After Latest FDA Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPSmcteldtZFZYVXNScUNxWlpTbmxMbWhwYlAtUjhVUHhOY2NtSWZPcURLZTdJci1MSWoyekVnOXRZbm5wdzVHSWlfeThpcThZVTJDZXppREVGY1pMV0l5X2dIWTR0Zm13S1p5cXJQcHpIU3RUcXFVWGF6ZUlTbVc0YXkyUHUwbmdCdXVOdnlOY3lrS2h3OXBlaG40dDY0anhqdHk5aA?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far", "summary": "Vera Therapeutics (VERA) is seeing investor interest after reaching an agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial. While recent stock performance shows a 7.84% rise over 7 days, it's down over 90 days and year-to-date, contrasting with strong longer", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-vera-stock-after-fda-trial-update-has-the-valuation-gap-gone-too-far-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-16T14:39:01", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com", "summary": "Fordyce Marshall, President and CEO of Vera Therapeutics, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, through a pre-arranged trading plan. Despite the insider sale and a year-to-date decline, the stock has seen an 81% return over the past year and i", "url": "https://uk.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-sells-679747-in-stock-93CH-4676593", "source_name": "Investing.com UK", "published_at": "2026-06-07T09:42:27", "published_display": "07 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics grants inducement awards to 10 new employees", "summary": "Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026. These awards include non-qualified stock options for 28,800 shares with an exercise price of $31.26 and restricted stock units (RSUs) for 14,150 shares. The awards were approved under Nasdaq Listing ", "url": "https://scanx.trade/stock-market-news/companies/vera-therapeutics-grants-inducement-awards-to-10-new-employees/42288284", "source_name": "scanx.trade", "published_at": "2026-06-06T04:14:00", "published_display": "06 Jun 2026 04:14", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Grants Inducement Stock Awards to New Employees", "summary": "Vera Therapeutics granted stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares to ten new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee in accordance with Nasdaq rules, aim to attract talent, with sto", "url": "https://www.quiverquant.com/news/Vera+Therapeutics+Grants+Inducement+Stock+Awards+to+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-06-05T20:12:00", "published_display": "05 Jun 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics gives new hires 28,800 stock option shares", "summary": "Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for ten new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants comprise 28,800 stock options at an exercise price of $31.26 and 14,150 Restricted Stock Units (", "url": "https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-d6uclrg70gfb.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:04:52", "published_display": "05 Jun 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy", "summary": "Vera Therapeutics announced alignment with the U.S. FDA for an earlier ORIGIN Phase 3 eGFR analysis for its drug atacicept, aiming for full approval in adults with IgA Nephropathy (IgAN). This revised schedule could lead to an sBLA submission in Q4 2026 and potential full approva", "url": "https://www.sahmcapital.com/news/content/vera-therapeutics-announces-alignment-with-us-fda-on-earlier-origin-phase-3-analysis-to-support-potential-full-approval-for-atacicept-in-adults-with-iga-nephropathy-2026-06-02", "source_name": "Sahm", "published_at": "2026-06-02T20:09:19", "published_display": "02 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQUFM5MUo1UVZ4RjJ3NkJCc0VPOUFNT2syNy1PT1g2ZENJblFTNWtqeUpjaEFRQTU3Rnk3M2VwQWF2M2RjU1ZRWVZvdWFsTEFkX0s3bVF6LXBWVjMwN25RZU5NREZYUUhrY3RIdkJ0WnZPam9tMnV2QjhlLXJkUk1LcjJ6YllCbHNCeWxvaGJaakVlaUx3NWxfME5fUEpob3doSFQxZ2NIT0xaa1oyQTdDOWpuTGdmdXdHeVZka0oxN0hyem5vWmVHd2tVMTlTSmZWRXVKTQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxORW9UZ1pzODl0Q1hEbWVrcjNIYk5PaXJ0bDFCUFo4TXJQbWwzRHlsX3pxUUg1V3htcmFBV2FpUnhCRXdJVjFacnZfMXM4d3poT0pkQUJnb1dJWi1xNk5RZElyU1JZd1JjX2t2T2NpangwTzRHS2xBVk1hZ0U0cS10d3poLUlFMlZNUUlQV1ZUbmNNSVozTFlGdHpVLWlkREpneTQzSjVOcHhQUHhvVUtv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading", "summary": "Vera Therapeutics (VERA) has granted a stock option for 17,084 shares of Class A Common Stock to director James R. Meyers. The options have an exercise price of $34.35 per share and will expire on May 20, 2036. Vesting is contingent on continuous service, occurring on the earlier", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-d85488941be0.html", "source_name": "Stock Titan", "published_at": "2026-05-29T08:10:15", "published_display": "29 May 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Vera Therapeutics (VERA) receives grant of 17,084 options", "summary": "Vera Therapeutics director Christy J. Oliger received a grant of 17,084 stock options at an exercise price of $34.35 per share, awarded as compensation. These options will fully vest on the earlier of the first anniversary of the grant date or the company's 2027 annual shareholde", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-12400e3effc7.html", "source_name": "Stock Titan", "published_at": "2026-05-27T18:39:45", "published_display": "27 May 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) awards director 17,084 stock options", "summary": "Vera Therapeutics director Michael Morrissey was granted 17,084 stock options for Class A Common Stock. These options have an exercise price of $34.35 and expire in 2036. They vest fully on the earlier of the first anniversary of the grant date or the company\u2019s 2027 annual stockh", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-3f5981c73657.html", "source_name": "Stock Titan", "published_at": "2026-05-27T04:09:59", "published_display": "27 May 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant", "summary": "Vera Therapeutics director Beth C. Seidenberg was granted stock options for 17,084 Class A common shares with an exercise price of $34.35 per share. These options are part of a compensation package and will vest fully on the earlier of the first anniversary of the grant date or t", "url": "https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-993cf9cc801a.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:16", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTWh5VlZjZElCcnYyR2NNb0lSWmtmRmhCWnA4TG1LMmhKOE9ZUlVGbnltdDRqWnZqck85cHpJeU9CUEo2blNqbDJlMkFLckN5M3E5V0liWjNSRVhvckpZQTF0Q2ZqVHEybDhJREQ5UDQ3OG9ET3poVEF0UXBmdXNHczc3VE5iUGQ5SEx2TGFacDFORFVGZ25mV2U4SXJ2MnRzZUxBUlZaQkYtYVpBeG9XTTNTWlhLUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxQTUFuNGgzYmVqT250SW5GcjJJbWE0ZzdaN1RSTWdMNTZFZzFZSzRzSV9mQjJUX3dyN1lBbEFFZjV2ODhxdGJUVHRoc3FfeDZrazlxVzhjUlhRVFd6U016WVI4LUJ5MVBwMl9vMV9WMVVXbjl2a3Q3QU1wQ1UweEVXOVN6Ylh4MFRjd05rNFlJMm56TlRlUXp6N2djWncwc1doamNNVTdYNFJPeHJMOFR6Ty14YnBDb0pJbUdvc19qWFh0YnptWE5fdFFSazZtR19NZXA1RTBYRTVBU0x4cmRzMlhRYVpMTEdqWFFVVC1meEIzXzlTdnFZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics to present May 13 at Bank of America health conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPYUhMaUoyRHFNcjV0UUVPWnk2S2p1c0RiZjdBRlRDMzdGN0gtODlTcHdGMlZuS0tZMDU3UElhZ0hQVGJkQ2JnRlhLcDBzQkxCNmxrMGxaTTVuWjBGX0RnWEJUNDJkVUx1OFhSZUtnZko3TjY4OTlqaE9aVnBzeFZERlRnYmUwX3hlN2E3ckhhR1Q0SERrSkZOaUF2bXdQTmRFeDFHWWZXNkN6d2hpTUZlTFdUNXl0N3hXTndaYnl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPYXV3RFJBQVo1Y0ZUam83R1FvUElLWTdmcHozR1ZvWWxnR25FQmo0NmdyVm43UmtZTGdWZEN5SFJzQ0h2SGRTa1FSUWFvMDFtMTVQck1ydndlTEFMNndwS1FZMk9lRWtVLWI2UGVfVVBaeU50c1lRM2JjVFA3anoweVV3ZG5ZcmFvYjY2Zl80TUlyazhyRExjeUtsYVprZ3hmODhHTjNLOA?oc=5", "source_name": "Market source", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPN3BIcEM0X0JQTzlQbmQwSUYwVXBKTmVMam9mMktFeDlBM1RzZlp2VHEwWUU4V1AzNWdQUjlwbXZIendtMjMtU21WdVF3eHZKeWlXNnBxQzIzbTgwdkdDWE8zNTlYbEdwQmVocjRKVFpKWk92eW0xUG1GVHBpSDdrOHo5aHBxdE9mLUZnbHZoZTZXLTF3dTYzaUE2MGp6eGFOczJab3BESUVmdWpncWpJbjR5c01wVE1jdFZKbERwYkFTN2x2a2xfaFVPZUNtTHN3QjZYZGZ1bDdpVHh3bldNTlctSEdJZ9IB6wFBVV95cUxOd0N5aXU0UlFUSmxoV1BaVm1qMTRCUW03MldhZ1JwWmU0Ni0tSXBOMU4wUXpaWGk0TzluTUlRZ0hSeUVwRHc1c3ZaWFN5b2prbHIzeG1tNTR2WUV5dmZQQzB3Zkw5V0dxZXZ4eXdvdlZhWnRyRWt3cW1vd2UtQTNiaVh1dWhPd19Mb1JONEJkcTRzUl9XZllHaHRJRHg3b2R5U192V1Y1bFNuM2JOZlRKQ1VmR0JKN0w4RVRlVWI0cGRLWUM1N3hwb05vMGZyVm9Zd1BzX1cxOWRUNklta3ctU1RGRlU5RGp6cUpN?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 57, "sentiment_summary": {"positive": 15, "negative": 3, "neutral": 39, "score": 53, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 38.5, "latest_week": "2026-07-17", "one_week_move": -8.3, "four_week_move": 9.7, "twelve_week_move": 2.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.526029, "market_dynamics_buy_signal": false, "relative_strength": -3.177098, "fair_value_gap": 19.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.8338, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.3% over one week, +9.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 12}, {"label": "simplywall.st", "count": 6}, {"label": "Sahm", "count": 5}, {"label": "Investing.com", "count": 5}, {"label": "MarketBeat", "count": 2}, {"label": "Simply Wall St.", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Regulatory and legal", "count": 13}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.3% over one week, +9.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA\u2019s Accelerated FDA Approval - Learn Why"}], "updated_at": "2026-07-18T19:13:51.961668+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}